NCT01248338 (NEMENDAS) is a Phase 4 clinical trial of metoprolol succinate in Hypertension, sponsored by Berlin-Chemie AG Menarini Group.

Who is sponsoring NCT01248338?

NCT01248338 is sponsored by Berlin-Chemie AG Menarini Group.

What drugs are being tested in NCT01248338?

Interventions in NCT01248338: metoprolol succinate, Nebivolol.

What condition does NCT01248338 study?

NCT01248338 studies Hypertension.

Is NCT01248338 still recruiting?

NCT01248338 is currently completed. Last updated 24 November 2010.

Last reviewed 2010-11-24 · How we verify

NCT01248338: NEMENDAS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison the Effects of Nebivolol Versus Metoprolol Succinate on Endothelial Function and Large Artery Stiffness

Completed Phase 4 Last updated 24 November 2010

What this trial tests

Phase 4 trial testing metoprolol succinate in Hypertension in 80 participants. Completed in 1 December 2009.

Timeline

1 March 2006

Primary endpoint
1 December 2008

1 December 2009

Quick facts

Lead sponsor	Berlin-Chemie AG Menarini Group
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	80
Start date	1 March 2006
Primary completion	1 December 2008
Estimated completion	1 December 2009
Sites	1 location across Estonia

Drugs / interventions tested

metoprolol succinate — full drug profile →
Nebivolol (nebivolol) — full drug profile →

Conditions studied

Hypertension — all drugs for Hypertension →

Sponsor

Berlin-Chemie AG Menarini Group — full company profile →

Who can join

Adults 30 to 65, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Effects of nebivolol and metoprolol on endothelial function
Time frame: 12 months
High-fidelity micromanometer (applanation tonometry) from both wrists and PWA, which is to be performed of the systolic portion (SphygmoCor Px, version 7.0) of the pulse curve.

Sponsor's own description

An impairment of endothelial function plays the central role in the pathogenesis of cardiovascular diseases and their complications. Most of cardiovascular risk factors are known to impair endothelial function and the established disease further aggravates endothelial dysfunction. The aim of the present study is to investigate the effects of nebivolol or metoprolol succinate on endothelial function and large artery stiffness.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of metoprolol succinate

Trials testing the same drug.

NCT00273052 — COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension · Phase 3 · completed

Other recruiting trials for Hypertension

Currently open trials in the same condition.

NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting

Other Berlin-Chemie AG Menarini Group trials

Trials by the same sponsor.

NCT07156916 — A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas® · Phase 1 · recruiting
NCT07201584 — A Comparative Bioavailability Study of Two Torasemide 10 mg Tablets Formulations in Healthy Adult Participants Under Fas · Phase 1 · recruiting
NCT07091669 — A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas® · Phase 1 · active not recruiting
NCT07146711 — A Comparative Bioavalability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, · Phase 1 · active not recruiting
NCT07036861 — A Comparative Bioavailability Study of Reformulated Ibuprofen 2% and 4% Oral Suspensions (Berlin Chemie AG) and Versus I · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01248338 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Berlin-Chemie AG Menarini Group
Last refreshed: 24 November 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01248338.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing